Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Orexigen Therapeutic (OREX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 46,820
  • Shares Outstanding, K 14,590
  • Annual Sales, $ 24,460 K
  • Annual Income, $ -68,690 K
  • 36-Month Beta 2.98
  • Price/Sales 1.89
  • Price/Book 0.64

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.67 +97.60%
on 12/30/16
3.98 -17.09%
on 01/05/17
+1.49 (+82.32%)
since 12/23/16
3-Month
1.65 +100.00%
on 12/14/16
3.98 -17.09%
on 01/05/17
+0.48 (+17.02%)
since 10/21/16
52-Week
1.65 +100.00%
on 12/14/16
19.80 -83.33%
on 01/25/16
-15.90 (-82.81%)
since 01/22/16

Most Recent Stories

More News
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU

Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.

Orexigen Therapeutics (OREX) Shares March Higher, Can It Continue?

Orexigen Therapeutics, Inc. (OREX) has been on the move lately as the stock has risen by 74.2% in the past four weeks, and it is currently trading well above its 20-Day SMA

Celgene Issues Preliminary 2016 Results, Lifts 2017 View

Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.

Alexion Blood Disorder Drug Gets Orphan Designation in U.S.

Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

The Medicines Co LDL-Lowering Drug Positive in Phase II

The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the...

Orexigen Therapeutics Highlights Key Business Priorities for 2017

Orexigen Therapeutics, Inc. (NASDAQ: OREX) today provided an update on recent progress and key business priorities for 2017 that will be covered during the Company's presentation at the 35th Annual J.P....

VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?

On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Consilient Health Ltd. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in the UK and Ireland

Orexigen Therapeutics, Inc. (NASDAQ:OREX) today announced that its wholly owned subsidiary Orexigen Therapeutics Ireland Ltd. and Consilient Health Ltd. have executed a commercialization and distributorship...

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave® (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Valeant Pharmaceuticals International, Inc. (Valeant), through a wholly owned subsidiary, will commercialize Contrave® (naltrexone HCl /...

Orexigen (OREX) Posts Narrower-than-Expected Loss in Q3

Orexigen (OREX) reported a loss of $1.01 per share in the third quarter of 2016, narrower than the Zacks Consensus Estimate of $2.13.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III...

See More

Support & Resistance

2nd Resistance Point 3.76
1st Resistance Point 3.53
Last Price 3.30
1st Support Level 3.14
2nd Support Level 2.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.